Prespecified Subgroup Analyses
diabetes
ATRIAL FIBRILLATION, DIABETES
A and B, Results of prespecified explorative subgroup analyses for the left ventricular mass index (A) and E/e′ ratio (B) primary end points. The following subgroups were analyzed: age (≤65 or >65 years at baseline), sex, body mass index (BMI [calculated as weight in kilograms divided by height in meters squared] of ≤30 or >30 at baseline), presence of diabetes, atrial fibrillation, β-blocker use as standard treatment, and geographic region. The interaction test eFigure 3 in A total of 428 AEs were recorded (213 and 215 in the mirabegron and placebo groups, respectively). These AEs affected a total of 170 patients (82 and 88 in the mirabegron and placebo groups, respectively; 